兰卫医学
(301060)
| 流通市值：31.06亿 | | | 总市值：34.89亿 |
| 流通股本：3.57亿 | | | 总股本：4.01亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,320,029,736.34 | 888,219,074.6 | 436,441,198.76 | 1,674,368,547.18 |
| 营业收入 | 1,320,029,736.34 | 888,219,074.6 | 436,441,198.76 | 1,674,368,547.18 |
| 二、营业总成本 | 1,298,282,175.55 | 855,557,139.79 | 410,500,506.73 | 1,685,215,697.99 |
| 营业成本 | 1,042,867,677.7 | 686,085,240.94 | 340,836,982.09 | 1,326,084,907.62 |
| 税金及附加 | 5,124,977.25 | 2,532,341.37 | 1,162,324.79 | 4,764,602.84 |
| 销售费用 | 57,780,785.6 | 37,796,605.13 | 17,250,547.64 | 98,687,788.48 |
| 管理费用 | 142,639,218.64 | 96,258,219.85 | 41,857,269.34 | 203,369,663.2 |
| 研发费用 | 44,916,908.61 | 29,468,611.63 | 9,985,811.02 | 48,862,579.58 |
| 财务费用 | 4,952,607.75 | 3,416,120.87 | -592,428.15 | 3,446,156.27 |
| 其中:利息费用 | 8,047,621.21 | 5,891,802.67 | 2,848,755.85 | 8,170,007.82 |
| 其中:利息收入 | 3,988,277.61 | 3,268,507.25 | 1,824,244.24 | 5,581,432.79 |
| 加:投资收益 | 4,523,572.46 | 4,474,306.88 | -221,690.31 | -2,119,270.49 |
| 资产处置收益 | -188,506.04 | 45,663.33 | -131,502.21 | 1,929,719.01 |
| 资产减值损失(新) | -68,176,621.46 | -4,712,939.41 | -1,635,412.86 | -28,941,990.66 |
| 信用减值损失(新) | -30,771,031.56 | -24,125,036.62 | -23,167,116.6 | -129,133,593.45 |
| 其他收益 | 11,996,181 | 4,272,791.29 | 1,936,000.12 | 33,288,596.45 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -60,868,844.81 | 12,616,720.28 | 2,720,970.17 | -135,823,689.95 |
| 加:营业外收入 | 1,176,151.87 | 925,273.8 | 249,518.13 | 589,878.01 |
| 减:营业外支出 | 4,980,552.14 | 2,351,113.07 | 651,766.29 | 18,009,492.8 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -64,673,245.08 | 11,190,881.01 | 2,318,722.01 | -153,243,304.74 |
| 减:所得税费用 | -11,494,048.52 | 1,104,184.05 | 2,583,548.55 | 8,466,100.16 |
| 六、净利润 | -53,179,196.56 | 10,086,696.96 | -264,826.54 | -161,709,404.9 |
| 持续经营净利润 | -53,179,196.56 | 10,086,696.96 | -264,826.54 | -161,709,404.9 |
| 归属于母公司股东的净利润 | -40,583,766.31 | 15,597,554.34 | 1,071,720.66 | -141,591,451.29 |
| 少数股东损益 | -12,595,430.25 | -5,510,857.38 | -1,336,547.2 | -20,117,953.61 |
| (一)基本每股收益 | -0.1 | 0.04 | 0 | -0.35 |
| (二)稀释每股收益 | -0.1 | 0.04 | 0 | -0.35 |
| 八、其他综合收益 | - | - | - | -653,308.3 |
| 归属于母公司股东的其他综合收益 | - | - | - | -653,308.3 |
| 九、综合收益总额 | -53,179,196.56 | 10,086,696.96 | -264,826.54 | -162,362,713.2 |
| 归属于母公司股东的综合收益总额 | -40,583,766.31 | 15,597,554.34 | 1,071,720.66 | -142,244,759.59 |
| 归属于少数股东的综合收益总额 | -12,595,430.25 | -5,510,857.38 | -1,336,547.2 | -20,117,953.61 |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |